Therapeutic psychedelics in mental health

Psychedelics have recently re-emerged as promising therapeutics for several neuropsychiatric disorders. Clinical studies have confirmed the efficacy of ketamine for the treatment of depression and suggest potential therapeutic properties of psilocybin, a naturally occurring psychedelic prodrug produced by more than 200 fungi.

While psychedelics could transform the landscape of treatments for many disorders, this field of research is still in its infancy. One of the main problems at the heart of modern psychedelic clinical research is that participants might easily be able to tell whether they have been given a placebo as compared to receiving hallucinogenic compounds.

In this regard, preclinical studies harbor several advantages including the possibility to conduct well-controlled experiments as well as using innovative tools to better understand the biological mechanisms mediating the behavioural effects. However, only a few studies have examined the effects of psilocybin in rodent disease models.


  • Demonstrate potential roles for psilocybin in the treatment of depression and obsessive-compulsive disorders using animal models.
  • Investigate potential mechanisms driving the therapeutical effect of psilocybin treatment.

Research team


  • James Gattuso
  • Nina Kleditzsch

Take part in this project

Student applications

Students who are applying to study at The Florey can register their interest in this project. Refer to our step-by-step guide to help you with your application.

How to apply

Accepting students

Contact us

If you’re interested in learning more about this project please contact our team.

Please enter your first name
Please enter your last name
Please enter a valid phone number
Please enter a correct email address
Please provide information regarding your enquiry